Research shows frailty levels rise significantly before dementia, suggesting it could be a key marker for early ...

Research and development expenses were $11.4 million for the third quarter ended September 30, 2024, compared to $11.7 million for the comparable period in 2023. The decrease was primarily related to ...

We will seek alignment with the FDA on a pivotal Phase 3 program design in light of recent findings relating to lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology ...

A new study has found frailty increases a person's risk of dementia, but early intervention may be the key to prevention.